Association of OPRK1 rs963549 and rs997917 polymorphisms with opioid use disorder and the related phenotypes

Ozkan-Kotiloglu S., AKYÜZLÜ D., Yalcin-Sahiner Ş., Ayaz N.

PHARMACOGENOMICS, cilt.24, sa.6, ss.325-334, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 6
  • Basım Tarihi: 2023
  • Doi Numarası: 10.2217/pgs-2023-0037
  • Dergi Adı: PHARMACOGENOMICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, MEDLINE
  • Sayfa Sayıları: ss.325-334
  • Anahtar Kelimeler: individual differences, opioid use disorder, opioid withdrawal, OPRK1 gene, kappa-opioid receptor, MESSENGER-RNA STABILITY, RECEPTOR GENE, OPIATE WITHDRAWAL, ALCOHOL DEPENDENCE, LOCUS-CERULEUS, DOPAMINE, DYNORPHIN, NEURONS, STRESS, SUSCEPTIBILITY
  • Ankara Üniversitesi Adresli: Evet

Özet

Aim: To evaluate the association between OPRK1 rs963549 and rs997917 and opioid use disorder (OUD) and related phenotypes.Methods: A sample of 208 individuals with (n = 100) and without (n = 108) OUD were enrolled. OPRK1 rs963549 and rs997917 were analyzed by PCR-RFLP. Craving, opioid withdrawal and the intensity of depressive and anxiety symptoms were measured by the appropriate scales.Results: OPRK1 rs963549 variation showed a trend of association with decreased opioid withdrawal. No significant associations were found between OPRK1 rs963549 and rs997917 polymorphisms and craving, depression or anxiety symptoms. Neither single OPRK1 SNPs nor OPRK1 haplotypes were associated with OUD.Conclusion: Our results could be useful for treatment failures of individuals who experience greater opioid withdrawal due to their OPRK1 rs963549 genotypes.